Table 1.
Patient Characteristics
| Characteristic | No. of Patients (%) | P | ||
|---|---|---|---|---|
| Total | B+PP (n=26) | PP (n=45) | ||
| Age, years | ||||
| Median | 55 | 58 | 54 | |
| Range | 27–76 | 27–76 | 34–74 | |
| ≥65 | 9 (12.7) | 4 (15.4) | 5 (11.1) | 0.880 |
| <65 | 62 (87.3) | 22 (84.6) | 40 (88.9) | |
| Sex | ||||
| Male | 34 (47.9) | 16 (61.5) | 18 (40.0) | 0.080 |
| Female | 37 (52.1) | 10 (38.5) | 27 (60.0) | |
| KPS score | ||||
| ≥80 | 63 (88.7) | 22 (84.6) | 41 (88.5) | 0.657 |
| <80 | 8 (11.3) | 4 (15.4) | 4 (11.5) | |
| Smoking status | ||||
| Never | 53 (74.6) | 19 (73.1) | 34 (75.6) | 0.817 |
| Ever | 18 (25.4) | 7 (26.9) | 11 (24.4) | |
| Histology | ||||
| Adenocarcinoma | 70 (98.6) | 25 (96.2) | 45 (100) | 0.366 |
| Others | 1 (1.4) | 1 (3.8) | 0 (0) | |
| Hypertension | ||||
| Yes | 14 (19.7) | 4 (7.7) | 10 (7.7) | 0.485 |
| No | 57 (80.3) | 22 (92.3) | 35 (92.3) | |
| EGFR mutation status assessment* | 39 | 19 | 20 | |
| Positive | 21 (53.8) | 9 (47.4) | 12 (60) | 0.527 |
| Wild type | 18 (46.2) | 10 (52.6) | 8 (40) | |
| Brain metastasis | ||||
| Symptomatic | 28 (39.4) | 9 (34.6) | 19 (42.2) | 0.527 |
| Asymptomatic | 43 (60.6) | 17 (65.4) | 26 (57.8) | |
Note: *Indicates that the patients’ EGFR mutation status was assessable.
Abbreviations: B+PP, bevacizumab plus pemetrexed-platinum; PP, pemetrexed-platinum; KPS, Karnofsky performance status; EGFR, epidermal growth factor receptor.